临床PI
叶定伟 教授
教授,博士生导师
E-mail: Dwyeli@163.com
 

  叶定伟教授,复旦大学附属肿瘤医院副院长、复旦大学前列腺肿瘤诊治研究中心主任,上海市抗癌协会前列腺肿瘤诊治中心主任、上海市泌尿外科学会副主任委员、中国抗癌协会泌尿肿瘤专业委员会候任主任委员、中国临床肿瘤学会(CSCO)免疫治疗专家委员会副主任委员、中国临床肿瘤学会常务理事和肾癌专家委员会副主任委员、中国抗癌协会家族遗传性肿瘤协作组副主任委员、NCCN肾癌诊治指南中国版编写组副组长、NCCN前列腺癌、膀胱癌和肾癌亚洲共识第二版的编写专家委员会委员、上海市抗癌协会理事长、中国肿瘤医院泌尿肿瘤协作组(UCOG)主任委员、国家卫计委全国县域医疗服务能力提升项目前列腺癌工作专家组牵头人、国家自然科学基金终审专家、中华医学科技奖评委、亚太前列腺癌学会(APPS)执行委员、亚洲冷冻治疗学会副主席。国家卫计委突出贡献医学专家,享受国务院特殊政府津贴。

        主持国家级、省部级科研基金40余项。发表论文445篇(SCI 213篇)。主编主译专著9本,发明专利7项。以第一完成人获上海市科技进步一等奖、教育部科技成果一等奖、上海市医学科技奖一等奖、中华医学奖二等奖,中国抗癌协会科技二等奖,2012年获国家科技进步一等奖(第三完成人)。获国家卫计委有突出贡献中青年专家、吴阶平泌尿外科医学奖,上海市领军人才,上海市医学领军人才,上海市优秀学科带头人、全国卫生计生系统先进工作者称号,享受国务院特殊政府津贴。


研究领域:

  擅长泌尿男性生殖系统肿瘤早期诊断、根治手术和综合治疗,尤其擅长前列腺癌、膀胱癌和肾癌的根治性手术。


研究团队:

  泌尿外科现有医师22人,其中正高2人、副高6人、主治8人、住院6人、科研护士3人。在读研究生20人。


代表性论著:

  1. Fu H#, Zhu Y, Wang Y, Liu Z, Zhang J, Xie H, Fu Q, Dai B, Ye D*, Xu J*: Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle Invasive Bladder Cancer. Clinical cancer research, 2018 Mar 7. doi: 10.1158/1078-0432.CCR-17-2687. [Epub ahead of print]
  2. Zhu Y#, Liu Z#, Wang Y, Fu H, Wang Z, Xie H, Zhang J, Li G, Dai B*, Ye D* et al: High CXC chemokine receptor 1 level represents an independent negative prognosticator in non-metastatic clear-cell renal cell carcinoma patients. Oncoimmunolog, 2017; 6(11):e1359450.
  3. Fangning Wan#, Yao Zhu, Chengtao Han, Qinghua Xu, Junlong Wu, Bo Dai, Hailiang Zhang, Guohai Shi, Weijie Gu, Dingwei Ye*. Identification and validation of soluble carrier family expression signature for predicting poor outcome of renal cell carcinoma. Journal of Cancer, 2017; 8(11): 2010-2017.
  4. Hai-Liang Zhang#, Xi-Nan Sheng, Xue-Song Li, Hong-Kai Wang, Zhi-Hong Chi, Zhi-Song He, Ding-Wei Ye*, Jun Guo*. Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors. BMC Cancer, 2017; 17:16.
  5. Junlong Wu#, Fangning Wan, Haoyue Sheng, Guohai Shi, Yijun Shen, Guowen Lin, Bo Dai, Yiping Zhu, Dingwei Ye*. NR1H3 Expression is a Prognostic Factor of Overall Survival for Patients with Muscle-Invasive Bladder Cancer. J Cancer, 2017; 8(5): 852–860.
  6. Yue Wang#, Fangning Wan, Kun Chang, Xiaolin Lu, Bo Dai, Dingwei Ye*. NUDT expression is predictive of prognosis in patients with clear cell renal cell carcinoma. Oncol Lett, 2017 Nov; 14(5): 6121–6128.
  7. Zhu Y#, Dai B, Zhang H, Shi G, Shen Y, Ye D*. Long non-coding RNA LOC572558 inhibits bladder cancer cell proliferation and tumor growth by regulating the AKT-MDM2-p53 signaling axis. Cancer Lett, 2016 Oct 1; 380(2):369-74.
  8. Wang H#, Wu J, Gu W, Wang B, Wan F, Dai B, Zhang H, Shi G, Shen Y, Zhu Y, Zhu Y, Ye D*.Serum Adiponectin Level May be an Independent Predictor of Clear Cell Renal Cell Carcinoma. J Cancer, 2016 Jun 27; 7(10):1340-6.
  9. Lu X#, Gu W, Zhang H, Zhu Y, Shi G, Ye D*.Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of Sunitinib. Oncotarget, 2016 May 3; 7(18):26879-87.
  10. Yao Zhu#, Dingwei Ye*. Preneoplastic and Primary Scrotal Cancer Updates on Pathogenesis and Diagnostic Evaluation. Urol Clin N Am, 2016; 43:523-530.
  11. Gu W#, Zhang G, Sun L, Ma Q, Cheng Y, Zhang H, Shi G, Zhu Y*, Ye D*. Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma. Journal of cachexia, sarcopenia and muscle, 2015; 6(3):222-230.
  12. Qu Y#, Chen H, Gu W, Gu C, Zhang H, Xu J, Zhu Y, Ye D*. Age-Dependent Association between Sex and Renal Cell Carcinoma Mortality: a Population-Based Analysis. Sci Rep, 2015 Mar 17; 5:9160.
  13. Zhu YP#, Ye DW*. Re: A report from #BlueJC: Can chewing gum prevent postoperative ileus? BJOG, 2015 Mar; 122(4):596.
  14. Zhu YP#, Dai B, Zhang HL, Shi GH, Ye DW*. Impact of preoperative 5α-reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. BMC Urol, 2015 Jun 2; 15:47.
  15. Lin GW#, Jia HX, Dai B, Zhang HL, Zhu Y, Shi GH, Ma CG, Ye DW*. Development of a preliminary nomogram to predict progression of bone scan for castration-resistant prostate cancer. Onco Targets Ther, 2015 Apr 7; 8:713-9.
  16. Li Q#, Gu C, Zhu Y, Wang M, Yang Y, Wang J, Jin L, Zhu ML, Shi TY, He J, Ye D*, Wei Q. Two novel PRKCI polymorphisms and prostate cancer risk in an Eastern Chinese Han population. Mol Carcinog, 2015 Aug; 54(8):632-41.
  17. Gu WJ#, Zhu Y, Wang HK, Zhang HL, Shi GH, Liu XH, Ye DW*. Prognostic value of components of body composition in patients treated with targeted therapy for advanced renal cell carcinoma: a retrospective case series. PLoS One, 2015 Feb 10; 10(2):e0118022.
  18. Zhu Y#, Gu WJ, Wang HK, Gu CY, Ye DW*. Surgical treatment of primary disease for penile squamous cell carcinoma: A Surveillance, Epidemiology, and End Results database analysis. OncolLett, 2015; 10(1):85-92.
  19. Zhang GM#, Zhu Y, Dong DH, Han CT, Gu CY, Gu WJ,Qin XJ, Sun LJ, Ye DW*. The association between metabolic syndrome and advanced prostate cancer in Chinese patients receiving radical prostatectomy. Asian J Androl, 2015 Sep-Oct; 17(5): 839–844.
  20. Zhang GM#, Gu CY, Zhu Y, Luo L, Dong DH, Wan FN, Zhang HL, Shi GH, Sun LJ, Ye DW*. ADIPOQ polymorphism rs182052 is associated with clear cell renal cell carcinoma. Cancer Sci, 2015 June; 106(6): 687–691.
  21. Dai B#, Kong YY, Chang K, Qu YY, Zhang SL, Zhang HL, Ye DW*. Primary invasive carcinoma associated with penoscrotalextramammary Paget's disease: A clinicopathologic analysis of 56 cases. BJU international, 2015; 115(1):153-160.
  22. Zhang GM#, Zhu Y, Gan HL, Wang HK, Shi GH, Zhang HL, Dai B, Wang CF, Ye DW*. Use of RENAL Nephrometry Scores for Predicting Tumor Upgrading Between Core Biopsies and Surgical Specimens: A Prospective Ex Vivo Study. Medicine (Baltimore), 2015 February; 94(8): e581.
  23. Zhu Y#, Wang HK, Qu YY, Ye DW*. Prostate cancer in East Asia: evolving trend over the last decade. Asian J Androl, 2015 Jan-Feb; 17(1): 48–57.
  24. Zhu YP#, Wang WJ, Zhang SL, Dai B, Ye DW*. Effects of gum chewing on postoperative ileus after cesarean section: A meta-analysis of randomised controlled trials. BJOG, 2014 Jun; 121(7):787-92.
  25. Zhu Y#Ye DW*. Prostate cancer: Alkaline phosphatase velocity in nonmetastatic CRPC. Nat Rev Urol, 2014 Dec; 11(12):666-7.
  26. Na R#, Ye D#, Liu F, Chen H, Qi J, Wu Y, Zhang G, Wang M, Wang W, Sun J, Yu G, Zhu Y, Ren S, Zheng SL, Jiang H, Sun Y*, Ding Q*, Xu J*. Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population. Prostate, 2014 Nov; 74(15):1569-75.
  27. Ye L#, Yao XD#, Wan FN#, Qu YY, ShenXX, Yu LZ, Li S, Wang N, Liu XJ, Dai B, Ye DW*. MS4A8B Promotes Cell Proliferation in Prostate Cancer. Prostate, 2014 Jun; 74(9):911-22.
  28. Wang HK# , Song XS#, Cheng Y, Qu YY, Zhang SL, Dai B, Zhang HL, Shen YJ, Zhu YP, Shi GH, Qin XJ, Ma CG, Lin GW, Xiao WJ, Zhu Y*Ye DW*. Visceral fat accumulation is associated with different pathological subtypes of renal cellcarcinoma (RCC): a multicentre study in China. BJU Int, 2014 Oct; 114(4):496-502.
  29. Cao DL#, Gu CY# ,Zhu Y, Dai B, Zhang HL, Shi GH, Shen YJ, Zhu YP,Ma CG, Xiao WJ, Qin XJ, Lin GW, Ye DW*. Polymorphisms at long non-coding RNAs and prostate cancer risk in an eastern Chinese population. Prostate Cancer and Prostatic Diseases, 2014 Dec; 17:315-319.
  30. Zhang GM#, Zhu Y#, Luo L, Zhang HL, Gu CY, Sun LJ, Ye DW*. Prevalence of dyslipidemia in patients with renal cell carcinoma: A case-control study in China. BJU Int, 2014 May; 113(5b):E75-81.
  31. Gu CY, Li QX, Zhu Y, Wang MY, Shi TY, Yang YY, Wang JC, Jin L, Wei QY, Ye DW*. Genetic variations of the ADIPOQ gene and risk of prostate cancer in Chinese Han men. Asian Journal of Andrology, 2014 Nov-Dec; 16(6):878-83.
  32. Shen YJ, Kong ZL, Wan FN, Wang HK, Bian XJ, Gan HL, Wang CF, Ye DW*. Downregulation of DAB2IP results in cell proliferation and invasion and contributes to unfavorable outcomes in bladder cancer. Cancer Science, 2014 Jun; 105(6):704-12.
  33. Wang P#Ye D#, Guo J, Liu F, Jiang H, Gong J, Gu C, Shao Q, Sun J, Zheng SL, Yu H, Lin X, Xia G, Fang Z, Zhu Y, Ding Q*, Xu J*. Genetic score of multiple risk-associated single nucleotide polymorphisms is a marker for genetic susceptibility to bladder cancer. Genes Chromosomes Cancer, 2014 Jan; 53(1):98-105.
  34. Ye L#, Li S, Ye D, Yang D, Yue F, Guo Y, Chen X, Chen F, Zhang J, Song X*: Livin expression may be regulated by miR-198 in human prostate cancer cell lines. European journal of cancer , 2013; 49(3):734-740.
  35. Zhu Y#, Wang HK#, Zhang HL, Yao XD, Zhang SL, Dai B, Shen YJ, Liu XH, Zhou LP, Ye DW*. Visceral obesity and risk of high grade disease in clinical t1a renal cell carcinoma. The Journal of urology, 2013 Feb; 189(2):447-53.
  36. Zhu YP#, Bian XJ, Yao XD, Zhang SL, Dai B, Shen YJ, Ye DW*. PA-MSHA inhibits proliferation and induces apoptosis via caspases dependent manner in the human bladder cancer cell lines. Oncology Letters, 2013; 5:1357-1362.
  37. Zhu YP#, Yao XD, Zhang SL, Dai B, Shen YJ, Wang CF, Ye DW*. Defining good candidates for extraperitoneal cystectomy: Results from random peritoneum biopsies of 136 cases. Urology, 2013 Apr; 81(4):820-5.
  38. Dai B#, Qu YY#, Kong YY, Yao XD, Zhang SL, Zhang HL, Yang WY, Ye DW*. Kinetics of testosterone recovery in clinically localized prostate cancer patients treated with radical prostatectomy and subsequent short-term adjuvant androgen deprivation therapy. Asian J Androl, 2013 Jul; 15(4):466-70.
  39. Zhang HL#, Qin XJ, Cao DL, Zhu Y, Yao XD, Zhang SL, Dai B, Ye DW*. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. Asian J Androl, 2013 Mar; 15(2):231-5.
  40. Zhu Y#, Zhou XY, Yao XD, Zhang SL, Dai B, Zhang HL, Shen YJ, Ye DW*. Prognostic value of carbonic anhydrase IX expression in penile squamous cell carcinoma: a pilot study. UrolOncol, 2013 Jul; 31(5):706-11.
  41. Zhu Y*, Wang HK#, Zhang HL, Yao XD, Zhang SL, Dai B, Shen YJ, Liu XH, Zhou LP, Ye DW*. Visceral obesity and risk of high grade disease in clinical t1a renal cell carcinoma. J Urol, 2013 Feb; 189(2):447-53.
  42. Li Q#, Gu C#, Zhu Y#, Wang M, Yang Y, Wang J, Jin L, Zhu ML, Shi TY, He J, Zhou X, Wei Q, Ye DW*. Polymorphisms in the mTOR Gene and Risk of Sporadic Prostate Cancer in an Eastern Chinese Population. PLoS One, 2013 Aug 5; 8(8):e71968.
  43. Shi GH#, Chen Y, Yao XD, Zhang SL, Dai B, Feng LQ, Zhang HL, Shen YJ, Zhu Y, Zhu YP, Xiao WJ, Ma CG, Wen LG, Qin XJ, Yang LF, Ye DW*. Individualized renal mass biopsy strategy for Chinese patients with different subtypes and necrosis area. Urol Oncol, 2013 Aug; 31(6):920-3.
  44. Qu YY#, Dai B, Kong YY, Chang K, Yao XD, Zhang SL, Zhang HL, Yang WY, Ye DW*. Influence of obesity on localized prostate cancer patients treated with radical prostatectomy. Asian Journal of Andrology, 2013; 15,747–752.
  45. Bian XJ#, Zhu Y, Shen YJ, Wang JY, Ma CG, Zhang HL, Dai B, Zhang SL, Yao XD, Ye DW*. The effectiveness of the TAX 327 nomogram in predicting overall survival in Chinese patients with metastatic castration-resistant prostate cancer. Asian J Androl, 2013; 15(5): 679–684.
  46. Dai B#, Qu YY, Kong YY, Yao XD, Zhang SL, Wang CF, Zhang HL, Yang WY, Ye DW*. Low pretreatment serum total testosterone is associated with high incidence of Gleason score 8-10 disease in prostatectomy specimens: data from Chinese localized prostate cancer patients. BJU Int, 2012 Dec; 110(11):667-672.
  47. Zhou JQ#, Zhu Y, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL, Shen YJ*: A nomogram to predict the duration of drainage in patients with penile cancer treated with inguinal lymph node dissection. J Urol, 2012; 187(1):129-133.
  48. Xu J#, Mo Z, Ye D, Wang M, Liu F, Jin G, Xu C, Wang X, Shao Q, Chen Z* et al. Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nature genetics, 2012; 44(11):1231-1235.
  49. Wang HK#, Zhu Y#, Yao XD, Zhang SL, Dai B, Zhang HL, Shen YJ, Wang CF, Ye DW*. External validation of a nomogram using RENAL nephrometry score to predict high grade renal cell carcinoma. J Urol, 2012; 187(5):1555-1560.
  50. Zhu Y#, Zhang HL, Yao XD, Zhang SL, Dai B, Shen YJ, Ye DW*. Development and evaluation of a nomogram to predict inguinal lymph node metastasis in patients with penile cancer and clinically negative lymph nodes. J Urol, 2010; 184(2):539-545.
  51. Ye D#, Mendelsohn J, Fan Z*. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clinical cancer research, 1999; 5(8):2171-2177.
  52. Ye D#, Li H, Qian S, Sun Y, Zheng J, Ma Y*. bcl-2/bax expression and p53 gene status in human bladder cancer: relationship to early recurrence with intravesical chemotherapy after resection. J Urol, 1998; 160(6 Pt 1):2025-2028; discussion 2029.
  53. Ye D#, Zheng J, Qian SX, Ma Y, Zheng X, Li D, Gu S*. p53 gene mutations in Chinese human testicular seminoma. J Urol, 1993; 150(3):884-886.
 
复旦大学肿瘤研究所 通讯地址: 东安路270号2号楼1312室 64175590-5312 Email:fuci2012@126.com
Copyright 2013 shca.org.cn All rights reserved. 复旦大学肿瘤研究所 版权所有